Annual Reports
Sun Pharma Annual Report 2025-26: A Review
Sun Pharma's Annual Report 2025-26 is a conventional statutory report, not an integrated one: a 16-page corporate overview, a ten-year table, a well-organised governance report and a BRSR with DNV reasonable assurance. The US FDA's OAI classifications at Halol and Baska, a US$200 million settlement involving Taro and a 38% fall in standalone profit are all disclosed, but only in the BRSR and the notes to the accounts.